Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Bionano Genomics, Inc. (BNGO)

Bionano Genomics Names Alex Hastie Chief Scientific Officer, Effective July 20

Neutral Impact 2 of 5 leadership Written later

Bionano Genomics said it has hired Alex Hastie, Ph.D., as Chief Scientific Officer, effective July 20, 2026. Dr. Hastie previously worked at the company for 14 years and helped develop its core optical genome mapping technologies, and he will lead the company's global scientific strategy and research initiatives. The filing gives no financial figures, and the appointment is an executive hire rather than a change in financial results.

Key points

  • Alex Hastie, Ph.D., appointed Chief Scientific Officer, effective July 20, 2026
  • Dr. Hastie previously spent 14 years at Bionano helping develop its core technologies
  • He will lead global scientific strategy, innovation roadmap and research initiatives
  • Announced by interim CEO and chairman Albert A. Luderer, Ph.D. in a June 24, 2026 press release

The filing

CompanyBionano Genomics, Inc. (BNGO)
Form8-K, current report
Filed with the SECJun 24, 2026, 8:30 AM ET
Accession number0001411690-26-000040

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.